Drug class
Investigational dual Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) inhibitor
Mechanism of action
Inhibits JAK1 and TYK2, reducing signalling downstream of cytokine receptors that use these kinases. This is a pharmacological description of the investigational molecule; it should not be represented as a currently authorised therapy or a product-specific clinical mechanism unless a marketing authorisation is confirmed.
General use cases
- Investigated for dermatomyositis and other immune-mediated inflammatory diseases. The catalogue entry is not assigned an authorised therapeutic indication without a current product label or marketing authorisation.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
